ZNRF2

Across TCGA pan-cancer cohorts, ZNRF2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZNRF2 data layer compared with 19 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZNRF2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZNRF2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where ZNRF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.875	0.550	.002	13	view →
PDAC	OS	Quartile	III,IV	0.937	0.331	.026	6	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	4	view →
UCEC	DFS	Tertile	II,III,IV	1.000	0.625	.024	4	view →
GBM	DFS	Median	All	0.282	0.454	.014	3	view →
HNSC	OS	Median	II,III,IV	1.000	0.954	.023	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZNRF2–CCRCC (OS)

Open the CCRCC breakdown →